Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells 703 Shares of Stock

TransMedics Group, Inc. (NASDAQ:TMDX) insider Anil P. Ranganath sold 703 shares of the firm’s stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $135.21, for a total transaction of $95,052.63. Following the completion of the sale, the insider now owns 8,809 shares of the company’s stock, valued at approximately $1,191,064.89. The transaction was disclosed in a document filed with the SEC, which is available at this link.

TransMedics Group Trading Up 0.6 %

Shares of NASDAQ:TMDX traded up $1.04 during trading on Friday, hitting $162.89. 742,292 shares of the company’s stock were exchanged, compared to its average volume of 769,601. TransMedics Group, Inc. has a 1-year low of $36.42 and a 1-year high of $171.98. The firm has a 50-day moving average price of $145.03 and a two-hundred day moving average price of $113.08. The company has a current ratio of 9.37, a quick ratio of 8.76 and a debt-to-equity ratio of 2.67. The firm has a market cap of $5.43 billion, a P/E ratio of -476.03 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, topping the consensus estimate of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The company had revenue of $114.30 million during the quarter, compared to analysts’ expectations of $98.84 million. During the same quarter in the previous year, the company earned ($0.03) EPS. TransMedics Group’s revenue was up 117.7% on a year-over-year basis. Equities analysts predict that TransMedics Group, Inc. will post 1.1 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Pitcairn Co. boosted its stake in TransMedics Group by 1.5% during the 1st quarter. Pitcairn Co. now owns 5,378 shares of the company’s stock worth $398,000 after acquiring an additional 78 shares during the last quarter. Signaturefd LLC boosted its stake in TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after acquiring an additional 93 shares during the last quarter. Arizona State Retirement System boosted its stake in TransMedics Group by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock worth $1,379,000 after acquiring an additional 186 shares during the last quarter. First Horizon Advisors Inc. boosted its stake in TransMedics Group by 26.8% during the 4th quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock worth $83,000 after acquiring an additional 222 shares during the last quarter. Finally, International Assets Investment Management LLC bought a new position in TransMedics Group during the 2nd quarter worth approximately $47,000. Institutional investors own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

TMDX has been the subject of several research reports. Oppenheimer raised their price objective on shares of TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a research report on Thursday, August 1st. Piper Sandler raised their price objective on shares of TransMedics Group from $170.00 to $180.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. Morgan Stanley raised their price objective on shares of TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. TD Cowen raised their price objective on shares of TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a research report on Friday, June 7th. Finally, JPMorgan Chase & Co. raised their price objective on shares of TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $166.88.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.